CERO THERAPEUTICS HOLDINGS, INC. (PBAX) Income Tax Expense (Benefit) USD 2021 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Cero Therapeutics Holdings, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2021 to 2023.
  • Cero Therapeutics Holdings, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $25.8 K, a 57.4% decline year-over-year.
  • Cero Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2023 was $94.8 K, a 84.2% decline from 2022.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $25.8 K -$34.7 K -57.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $44.7 K Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q3 2022 $60.5 K +$60.5 K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q3 2021 $0 Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.